MedTrace Logo

Quantitative mpMRI to Predict Metastatic Potential of Prostate Cancer

NCT05252806 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-06-22

No results posted yet for this study

Summary

The primary aim of this study is to assess the potential of quantitative MRI measurements to predict localized prostate cancer T-stage and disease spread to nodes (N-stage) by correlating quantitative MRI measurements of the local prostate to the presence of metastases as seen on PSMA-PET/CT.

Conditions

Interventions

DIAGNOSTIC_TEST

MRI examination of the prostate

Participants will undergo one MRI examination of approximately 45 minutes including an intramuscular injection with an antispasmodic agent to minimize bowel movement

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Tom Scheenen · Radboud University Medical Center

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05252806 on ClinicalTrials.gov